

LITERATURA

- Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. *Clin Exp Nephrol.* 2013;17:603-606.
- Alpsoy E. Cutaneous vasculitis; an algorithmic approach to diagnosis. *Front Med (Lausanne).* 2022;9:1012554.
- Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. *Intern Emerg Med.* 2021;16:831-841.
- Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). *Ann Rheum Dis.* 2009;68:1827-1832.
- Houben E, Bax WA, van Dam B, et al. Diagnosing ANCA-associated vasculitis in ANCA-positive patients: a retrospective analysis on the role of clinical symptoms and the ANCA titre. *Medicine (Baltimore).* 2016;95(40):e5096.
- Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. *Arthritis Rheum.* 2009;61(10):1454-1461.
- Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. *Ann Rheum Dis.* 2022;81:1647-1653.
- Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. *Ann Rheum Dis.* 2024;83(6):741-751.
- Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. *Medicine (Baltimore).* 1961;40:1-30.
- Vanderschueren S, Del Biondo E, Ruttens D, et al. Inflammation of unknown origin versus fever of unknown origin: two of a kind. *Eur J Intern Med.* 2009;20(4):415-418.
- Bleeker-Rovers CP, Vos FJ, de Kleijn EMHA, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. *Medicine (Baltimore).* 2007;86(1):26-38.
- Béra S, Jamilloux Y, Gerfaud-Valentin M, et al. Inflammation of unknown origin: evaluation and prognosis of 57 cases. *J Clin Med.* 2021;11(1):32.
- Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. *Ann Rheum Dis.* 2024;83:30-47.
- Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. *N Engl J Med.* 2020;382(7):622-631.
- Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med.* 2017;377(4):317-328.
- Blockmans D, Penn SK, Setty AR, et al. A phase 3 trial of upadacitinib for giant-cell arteritis. *N Engl J Med.* 2025;392(20):2013-2024.
- Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *N Engl J Med.* 2017;376(20):1921-1932.
- Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. *N Engl J Med.* 2024;390(10):911-921.
- Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. *N Engl J Med.* 2021;384(7):599-609.
- Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis.* 2020;79:19-30.



ČESKÁ
INTERNISTICKÁ
SPOLEČNOST

Česká internistická společnost ČLS JEP pořádá

SEMINÁŘ K ATESTAČNÍM OTÁZKÁM PRO MLADÉ INTERNISTY

17. září 2026

NOVOTEL Praha Wenceslas Square
(Kateřinská 38, Praha 2)

Možnost přihlášení na seminář do 10. 9. 2026
na e-mailové adrese: v.strukova@gsymposion.cz

XXXII. KONGRES ČESKÉ INTERNISTICKÉ SPOLEČNOSTI ČLS J. E. PURKYNĚ

ve spolupráci s dalšími
odbornými společnostmi
a s Interní sekci
České asociace sester



ČESKÁ
INTERNISTICKÁ
SPOLEČNOST



NADAČNÍ FOND
ČESKÉ
INTERNY



ČESKÁ
ASOCIACE
SESTER

6. – 9. 12. 2026

Kongresové centrum Praha
5. května 1640/65, Praha 4

www.kongresCIS.cz